Upon failure of chemotherapy plus EGFR antibodies, CRC patients usually stop additional EGFR antibodies, while re-challenge of EGFR antibodies could provide clinical benefits in molecularly selected patients beyond second line [123]. Here, EGFR is linked to colorectal carcinoma.